Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies

Nester, C., Appel, G. B., Bomback, A. S., Bouman, K. P., Cook, H. T., Daina, E., Dixon, B. P., Rice, K., Najafian, N., Hui, J., Podos, S. D., Langman, C. B., Lightstone, L., Parikh, S. V., Pickering, M. C., Sperati, C. J., Trachtman, H., Tumlin, J., de Vries, A. P., … Remuzzi, G. (2022). Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. American Journal of Nephrology, 53(10), 687–700. Portico. https://doi.org/10.1159/000527167
Authors:
Carla Nester
Gerald B. Appel
Andrew S. Bomback
Koenraad Peter Bouman
H. Terence Cook
Erica Daina
Bradley P. Dixon
Kara Rice
Nader Najafian
James Hui
Steven D. Podos
Craig B. Langman
Liz Lightstone
Samir V. Parikh
Matthew C. Pickering
C. John Sperati
Howard Trachtman
James Tumlin
Aiko Pj De Vries
Jack F.M. Wetzels
Giuseppe Remuzzi
Affiliated Authors:
Gerald B. Appel
Andrew S. Bomback
Author Keywords:
c3 glomerulopathy
factor d inhibitor
complement alternative pathway
danicopan
clinical trial
Publication Type:
Article
Unique ID:
10.1159/000527167
PMID:
Publication Date:
Data Source:
Scopus

Record Created: